Key Takeaways
- •On April 28, 2026, Health Canada authorized the first generic version of injectable semaglutide for sale.
- •High costs have long prevented many Canadians from using these treatments despite growing clinical evidence.
- •Canada's pricing framework for generics reduces costs as more versions enter the market.
Canada Approves First Generic Semaglutide: Prices and Timeline
On April 28, 2026, Health Canada authorized the first generic version of injectable semaglutide for sale. Canada became the first G7 nation to approve such a generic. This step addresses access issues for over 10 million Canadians previously limited by high costs.
Expanding Access Through Lower Prices
High costs have long prevented many Canadians from using these treatments despite growing clinical evidence. Affordability stands as the main barrier, not a lack of need. A study conducted with Angus Reid found that at $100 per month, nearly six times more Canadians would consider these treatments compared to $400 per month.
Canada's pricing framework for generics reduces costs as more versions enter the market. With one generic, the estimated price reaches $240 per pen, about 75 percent of the brand price of $320 per pen. Two generics drop it to $160 per pen, around 50 percent, while three or more bring it to $112 per pen, roughly 35 percent.
These lower prices could enable about 29 percent of eligible Canadians to begin treatment. For precise calculations on costs, check the Cost Per Dose Calculator.
Low Awareness of Generic Options
Despite the importance of this development, only 23 percent of Canadians knew generics were approaching, according to research. While 97 percent had heard of these medications, just 31 percent had seriously considered using one. This information gap goes beyond pricing and highlights limited details on the science involved.
Better patient information leads to improved outcomes. Researchers and health platforms play a key role in filling these gaps. The Peptide Glossary offers clear definitions for compounds like semaglutide.
Rollout Timeline and Next Steps
With the Notice of Compliance issued to the first generic manufacturers, attention turns to supply distribution. Generic semaglutide may become available in Canada as early as June 2026. Updates on availability will follow as production ramps up.
Planning dosage and cycles helps with preparation. Use the Dosage & Cycle Planner for research purposes.
Details from the Angus Reid Study
The study was commissioned by a health organization and conducted by Angus Reid. It ran from December 11 to 15, 2025. For comparison, a probability sample of this size yields a margin of error of ±3 percent, 19 times out of 20.
Key findings include the pricing sensitivity and awareness levels noted earlier. Generational differences appear, with those aged 18 to 34 least likely to consult professionals. These insights underscore the need for accessible, informed care.
A Milestone for Canadian Healthcare
This approval marks science-backed care becoming available to more people, not just a select few. Over 10 million Canadians stand to benefit from reduced prices and wider access. The shift supports better management of health needs across the population.
For the latest updates, visit Latest peptide news.
Related Research Compounds
Looking for high-purity research peptides? Browse our catalog for HPLC-verified compounds.
| Compound | Purity | Size | Price |
|---|---|---|---|
| Semaglutide 10mg | >99% | 10mg | $49.00 |